A tighter archive for life-science signals.
Search once, then narrow by source or topic.
Novartis' Rhapsido shows promise in Phase 2 food allergy data
Novartis' Rhapsido shows promise in Phase 2 food allergy data
Atrium arises from Novartis' Avidity buy with $270M, pair of preclinical cardio candidates
Atrium arises from Novartis' Avidity buy with $270M, pair of preclinical cardio candidates
Novartis, Takeda to enter next Medicare drug price negotiations
Novartis, Takeda to enter next Medicare drug price negotiations
CHMP recommends Moderna's flu-Covid shot and Novartis pill for hives
CHMP recommends Moderna's flu-Covid shot and Novartis pill for hives
Novartis closes Avidity deal as rare heart disease spinout launches
Novartis closes Avidity deal as rare heart disease spinout launches
Novartis to build another radioligand factory; Germany steps up probe into Gerresheimer
Novartis to build another radioligand factory; Germany steps up probe into Gerresheimer
Madrigal sees a stock sell-off; ex-Novartis exec heads to Daiichi
Madrigal sees a stock sell-off; ex-Novartis exec heads to Daiichi
Novartis to divest India unit to private equity-led consortium for $159M
Novartis to divest India unit to private equity-led consortium for $159M
Daiichi picks former Novartis CMO John Tsai to head up R&D
Daiichi picks former Novartis CMO John Tsai to head up R&D
Novartis winds down ph. 1 solid tumor program after lacking efficacy
Novartis winds down ph. 1 solid tumor program after lacking efficacy
Novartis finds natural partner in macrocycle biotech, inking $1.7B-plus cardio deal
Novartis finds natural partner in macrocycle biotech, inking $1.7B-plus cardio deal
Updated: Novartis signs macrocyclic deal with Unnatural Products
Updated: Novartis signs macrocyclic deal with Unnatural Products
Novartis signs macrocyclic deal with Unnatural Products for $100M upfront
Novartis signs macrocyclic deal with Unnatural Products for $100M upfront
Lilly's Zepbound, Taltz combo data in psoriasis and weight loss; Novartis bolsters Rhapsido results
Lilly's Zepbound, Taltz combo data in psoriasis and weight loss; Novartis bolsters Rhapsido results
Novartis shakes up early pipeline with 6 culls and 2 new cancer candidates
Novartis shakes up early pipeline with 6 culls and 2 new cancer candidates
Novartis says generics to erode $4B from 2026 sales
Novartis says generics to erode $4B from 2026 sales
Novartis discovers new CDK inhibitors
Novartis discovers new CDK inhibitors
Novartis licenses radiopharma asset from Chinese biotech for $50M upfront
Novartis licenses radiopharma asset from Chinese biotech for $50M upfront
Brand directory, kept in view
A rolling strip of the companies, platforms, CROs and device makers that show up across the coverage.
Open about page